Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs MDMA

MDMA therapy: Side effects appear mild, but there are problems with the evidence

by Eric W. Dolan
August 8, 2024
in MDMA
Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

In recent years, MDMA-assisted psychotherapy has garnered attention for its potential to treat psychiatric conditions such as post-traumatic stress disorder (PTSD). However, understanding the safety profile of this treatment is important before it becomes widely implemented. A recent comprehensive systematic review and meta-analysis published in Neuropsychopharmacology provides valuable insights into the side effects associated with MDMA-assisted psychotherapy.

The study found that while MDMA-assisted psychotherapy is associated with increased odds of side effects compared to a placebo, these side effects are generally mild to moderate and transient. However, significant gaps in the existing evidence highlight the need for further research to better understand the safety of MDMA-assisted psychotherapy and guide its clinical use.

MDMA, short for 3,4-methylenedioxymethamphetamine, is a synthetic drug that alters mood and perception. It is commonly known by street names such as ecstasy or molly. MDMA is known for producing feelings of euphoria, increased energy, emotional warmth, and distorted sensory and time perception.

MDMA-assisted psychotherapy combines the administration of MDMA with structured psychotherapy sessions. The premise of MDMA-assisted psychotherapy is that MDMA can enhance the therapeutic process by reducing fear and anxiety associated with recalling traumatic memories, thus allowing patients to process these memories more effectively.

Typically, the treatment involves several preparatory psychotherapy sessions without MDMA, followed by a few full-day sessions where MDMA is administered under close supervision. These MDMA sessions are followed by integration sessions to help patients process their experiences and insights gained during the MDMA-assisted sessions.

While initial studies have shown promising results, concerns remain about the potential side effects and the adequacy of safety reporting in existing studies. The researchers aimed to address these concerns by conducting the first meta-analysis of the side effects of MDMA-assisted psychotherapy across various psychiatric conditions.

“I have been working on research related to MDMA for many years. We are currently starting an MDMA-assisted psychotherapy clinical trial and wanted to understand as best as we can what the likely side effects of this treatment could be. We conducted this study to get a comprehensive understanding of the safety of MDMA-assisted psychotherapy based on existing data,” said study author Gillinder Bedi, an associate professor Gill Bedi at the University of Melbourne and head of substance use research at Orygen.

To provide a thorough assessment, they searched multiple databases, including PubMed, EMBASE, and Cochrane Central Register of Controlled Trials, for studies involving MDMA combined with psychotherapy for psychiatric conditions. Only Phase 2 and 3 studies were included, as these provide more rigorous data compared to earlier phase trials.

The final analysis included 13 studies that met the inclusion criteria, totaling 333 participants. Eight of these studies were randomized controlled trials (RCTs) with 298 participants, which formed the primary basis for the meta-analysis.

The researchers extracted detailed data from these studies, including the study design, participant demographics, MDMA dosage, control conditions, side effects, and reasons for study withdrawal. They assessed the quality of side effect reporting using the CONSORT Harms 2022 guidelines, a 17-item checklist designed to ensure comprehensive reporting of adverse events in clinical trials.

Bedi and her colleagues found that participants undergoing MDMA-assisted psychotherapy had a higher likelihood of experiencing side effects compared to those receiving a placebo. In Phase 2 studies, 45% of participants in the MDMA-assisted psychotherapy group reported side effects during medication sessions, compared to 30% in the placebo group.

Similarly, 46% of MDMA-assisted psychotherapy participants reported side effects within seven days following the sessions, compared to 31% in the placebo group. Common side effects included anxiety, jaw clenching, muscle tightness, nausea, and decreased appetite. These side effects were generally mild to moderate in severity and transient.

In Phase 3 studies, the odds of experiencing any treatment emergent adverse event (TEAE) were higher for participants in the MDMA-assisted psychotherapy group compared to the placebo group, with 16% of MDMA-assisted psychotherapy participants reporting TEAEs compared to 5% of those in the placebo group.

Specific side effects that were more common in the MDMA-assisted psychotherapy group included muscle tightness, decreased appetite, nausea, excessive perspiration, feeling cold, restlessness, dilated pupils, jaw clenching, uncontrolled eye movements, feeling jittery, non-cardiac chest pain, blurred vision, and chills. Despite these increased odds, the side effects were again generally mild to moderate and resolved within a short period.

Importantly, the researchers did not find significant differences in the rates of serious adverse events or study withdrawal between the MDMA-assisted psychotherapy and placebo groups. This suggests that while MDMA-assisted psychotherapy is associated with a higher likelihood of experiencing side effects, these effects are typically not severe enough to cause participants to withdraw from the study.

But the researchers highlighted several limitations in the existing evidence. The certainty of the evidence was rated as very low for most Phase 2 side effect outcomes and low to moderate for Phase 3 outcomes. This was primarily due to the small number of studies, the selective nature of the participant samples, and the heterogeneous methods used to assess and report side effects. Additionally, many studies relied on passive monitoring of side effects, which likely underestimates their prevalence.

“We found that, based on a comprehensive assessment of the existing data, the side effects of MDMA-assisted psychotherapy appear to be mild to moderate and relatively transient,” Bedi told Psypost. “While that is reassuring, we also found that there are methodological limitations that mean the certainty of existing evidence is not strong. This means that we don’t yet have a good sense of what the side effects are, particularly in relation to MDMA-assisted therapy used in ‘real world’ clinical settings rather than in tightly controlled trials.”

To address these limitations, the researchers recommend that future studies use systematic methods for assessing side effects, including structured checklists or scales, and ensure transparency in reporting all potential side effects. There is also a need for long-term follow-up studies to better understand the enduring effects of MDMA-assisted psychotherapy.

“There was some data which was not reported in the papers and which we were not able to access from the authors,” Bedi noted. “However, we do not think this would be likely to affect our findings substantially. The other thing to be aware of is that as part of a recent report by ICER on MDMA-assisted psychotherapy, there have been allegations that some serious adverse events were not actually recorded or reported appropriately. Obviously, we were only able to base our review on the evidence that has been made available by the researchers and sponsors of this research.”

In addition, most of the existing studies were sponsored by a single advocacy group. Independent research is crucial to provide unbiased evidence on the safety and efficacy of MDMA-assisted psychotherapy, particularly as it moves closer to potential approval for clinical use in treating PTSD and other psychiatric conditions.

“I am hopeful that with more independent research groups conducting high-quality research, we will get more robust evidence on both the benefits and potential harms of MDMA-assisted psychotherapy in the coming years,” Bedi said. “Our group is particularly focusing on doing our best to address the methodological issues that have been raised in relation to existing research, and on making sure the approach to psychotherapy we use is evidence-based and also informed by what is currently known or hypothesized about the likely mechanisms of action of this approach.”

The study, “Side-effects of MDMA-assisted psychotherapy: a systematic review and meta-analysis,” was authored by Julia Colcott, Alexandre A. Guerin, Olivia Carter, Sally Meikle, and Gillinder Bedi.

TweetSendScanShareSendPinShareShareShareShareShare

RELATED

Researchers identify neural mechanism behind memory prioritization
MDMA

New study reveals how MDMA rewires serotonin and oxytocin systems in the brain

June 30, 2025

Researchers found that MDMA reduces anxiety and enhances social behavior in zebrafish by altering key neurochemical systems. The drug suppressed serotonin signaling, boosted oxytocin receptor expression, and modulated brain signaling proteins involved in emotional regulation.

Read moreDetails
Is childhood trauma linked to challenging ayahuasca experiences? New study has surprising answer
LSD

New study shows LSD changes brain connectivity in unique ways compared to MDMA and amphetamines

March 27, 2025

A new brain imaging study finds LSD alters brain connectivity in unique ways, setting it apart from MDMA and amphetamine despite some shared effects.

Read moreDetails
New research reveals distinct cognitive effects of psychedelics and MDMA
LSD

New research reveals distinct cognitive effects of psychedelics and MDMA

August 22, 2024

Psychedelics impair attention and decision-making during use but may boost creativity afterward. In contrast, MDMA primarily disrupts memory, with no lasting cognitive benefits—highlighting the complex, varied effects of these substances on the brain.

Read moreDetails
Researchers shed light on the neurobiological mechanism behind MDMA’s empathy-enhancing effects
MDMA

Researchers shed light on the neurobiological mechanism behind MDMA’s empathy-enhancing effects

June 27, 2024

MDMA enhances empathy-like behaviors in mice through serotonin release in the nucleus accumbens, with significant effects in males but not females, and reverses empathy deficits in a mouse model of autism spectrum disorder.

Read moreDetails
MDMA found to have an interesting impact on emotional processing in the brain
MDMA

MDMA found to have an interesting impact on emotional processing in the brain

June 19, 2024

Researchers found that MDMA enhances the brain's response to emotional faces, particularly happy and angry ones, distinguishing its effects from methamphetamine and highlighting its unique impact on social and emotional processing.

Read moreDetails
Long-COVID defeated by psychedelics? Case study details unusual recovery
COVID-19

Long-COVID defeated by psychedelics? Case study details unusual recovery

May 29, 2024

A 41-year-old woman with Long-COVID reportedly experienced significant symptom relief after using psilocybin and MDMA, but the effectiveness and safety of these psychedelics for Long-COVID remain uncertain and require further research.

Read moreDetails
New study reveals MDMA’s unique influence on positive social feedback
MDMA

New study reveals MDMA’s unique influence on positive social feedback

February 26, 2024

MDMA enhances positive responses to social feedback without affecting negative responses. This sheds light on MDMA's potential in treating social processing impairments, spotlighting its unique empathogenic effects.

Read moreDetails
Could MDMA offer new hope for borderline personality disorder treatment?
MDMA

Could MDMA offer new hope for borderline personality disorder treatment?

February 6, 2024

Interviews with clinicians reveal potential benefits of MDMA-assisted therapy for Borderline Personality Disorder (BPD), suggesting similarities with PTSD treatment. The study, published in the Journal of Psychedelic Studies, calls for further research into MDMA's efficacy for BPD.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Othello syndrome: Woman’s rare stroke leads to psychotic delusions of infidelity

How to protect your mental health from a passive-aggressive narcissist

Dark personality traits linked to generative AI use among art students

Scientists are uncovering more and more unsettling facts about our politics

People with depression face significantly greater social and health-related challenges

Stress disrupts gut and brain barriers by reducing key microbial metabolites, study finds

New research reveals hidden biases in AI’s moral advice

7 subtle signs you are being love bombed—and how to slow things down before you get hurt

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy